Pfizer OTC strategy
This article was originally published in The Tan Sheet
Executive Summary
Company is "investing in advertising and marketing to reinvigorate our portfolio of leading brands [including] BenGay [and] Plax," Pfizer Exec VP and CFO Henry McKinnell, PhD, commented to securities analysts on Feb. 26. "Further expansion will come through the addition of entire new product lines through our internal research efforts, licensing and acquisitions." Pfizer consumer product sales grew 1% in 1992. In addition, McKinnell suggested that the nonsedating antihistamine Reactine (cetirizine) "may be an interesting candidate" for Rx-to-OTC switch even though the recent relabeling of the other drugs in the class, Marion Merrell Dow's Seldane (terfenadine) and J&J's Hismanal (astemizole), could jeopardize their switch potential. An NDA for prescription marketing of Reactine has been pending at FDA since June 1988.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning